Bambusa Therapeutics, Inc.
Biological Products, (No Diagnostic Substances), SIC 2836 · Incorporated in Delaware
Follow- Filed
- Oct 9, 2026
- Pages
- 338
- Underwriters
- 4
Road to listing
67 days from first draft to public filing- Draft submittedAug 3 · DRSA first draft of the registration statement, sent to the SEC in confidence.0001628280-26-051869
- Draft amendedSep 15 · DRS/A0001628280-26-061935
- Filed in publicOct 9 · S-1The registration statement, public for the first time.0001628280-26-065557
- AmendedToday · S-1/AThe registration statement, revised.0001628280-26-067119
- RoadshowNot yet · FWPA company that filed drafts in confidence must file in public at least 15 days before its roadshow begins.
- EffectiveNot yet · EFFECTThe SEC declares the registration statement effective, and the shares can be sold.
- PricedNot yet · 424B4The final prospectus, with the price the shares sold at.
- First tradeNot yet · BBTXThe shares open on the exchange, and the desk covers the company in full.
The company sent the SEC 2 drafts in confidence over 67 days, then filed in public on October 9, 2026. The dashed stops are still to come.
Cash
Jun 30, 2026p. F-32
Total assets
Jun 30, 2026p. F-32Liabilities $12.22M
Reading
Thaler Agent, each line on its passageBalance sheet
As filed, in the prospectus’s own lines.
| Line | Dec 31, 2024 | Dec 31, 2025 | Jun 30, 2026 |
|---|---|---|---|
| Cash and cash equivalents | |||
| Marketable securities | — | ||
| Working capital | — | — | |
| Prepaid expenses and other current assets | |||
| Total current assets | |||
| Deferred offering costs | — | — | |
| Other assets | — | ||
| Total assets | |||
| Total liabilities | — | — | |
| Convertible preferred stock | — | — | |
| Total stockholders’ (deficit) equity | — | — | |
| Accounts payable | |||
| Accrued expenses and other current liabilities | |||
| Total current liabilities | |||
| Series Seed convertible preferred stock | |||
| Series Seed Plus convertible preferred stock | |||
| Series A-1 convertible preferred stock | — | ||
| Series A-2 convertible preferred stock | — | ||
| Common stock | — | — | — |
| Additional paid-in capital | |||
| Accumulated other comprehensive (loss) income | — | ||
| Accumulated other comprehensive income | — | — | |
| Accumulated deficit | |||
| Total stockholders' deficit | |||
| Total liabilities, convertible preferred stock, and stockholders' deficit |
Read from the prospectus’s tables, merged into one statement: the audited financial statements first, every other table checked against them.
From SEC EDGAR · Form S-1/A · 0001628280-26-067119 · filed October 26, 2026